These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 8905479)

  • 1. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S; Ren SG; Braunstein GD; Melmed S
    J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency.
    Skjaerbaek C; Frystyk J; Kaal A; Laursen T; Møller J; Weeke J; Jørgensen JO; Sandahl Christiansen J; Orskov H
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):25-33. PubMed ID: 10651750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide.
    Fredstorp L; Werner S; Bang P; Hall K
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):495-501. PubMed ID: 7525123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
    Lorcy Y; Dejager S; Chanson P;
    Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients.
    Juul A; Main K; Blum WF; Lindholm J; Ranke MB; Skakkebaek NE
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):85-93. PubMed ID: 7519529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
    J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle.
    Juul A; Scheike T; Pedersen AT; Main KM; Andersson AM; Pedersen LM; Skakkebaek NE
    Hum Reprod; 1997 Oct; 12(10):2123-8. PubMed ID: 9402266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P; Zwimpfer C; Zapf J; Schmid C
    Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients.
    Laursen T; Møller J; Fisker S; Jorgensen JO; Christiansen JS
    Growth Horm IGF Res; 1999 Dec; 9(6):451-7. PubMed ID: 10629166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization.
    Parkinson C; Flyvbjerg A; Trainer PJ
    Growth Horm IGF Res; 2004 Feb; 14(1):59-65. PubMed ID: 14700556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex.
    Barreca A; Cariola G; Ponzani P; Arvigo M; Foppiani L; Giordano G; Minuto F
    Clin Endocrinol (Oxf); 1995 Feb; 42(2):161-7. PubMed ID: 7535670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.